Adverse renal effects of anti‐inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors
暂无分享,去创建一个
[1] M. Perretti,et al. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. , 2003, Biochemical pharmacology.
[2] Roger H Jones. Efficacy and safety of COX 2 inhibitors , 2002, BMJ : British Medical Journal.
[3] G. Thornicroft,et al. The global response to mental illness , 2002, BMJ : British Medical Journal.
[4] A. Kurtz,et al. Cyclo‐oxygenase‐2 inhibition increases blood pressure in rats , 2002, British journal of pharmacology.
[5] K. Brune,et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet , 2002, Clinical pharmacology and therapeutics.
[6] A. Whelton,et al. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. , 2002, Clinical therapeutics.
[7] D. Zamir,et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone , 2002, Journal of Human Hypertension.
[8] C. Nzerue,et al. Celecoxib-induced acute interstitial nephritis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] D. B. Rodgers,et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273] , 2002, BMC family practice.
[10] M. Armoni,et al. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. , 2002, The Journal of emergency medicine.
[11] W. White,et al. Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors , 2002, Hypertension.
[12] R. Bing,et al. Nitric Oxide, Anti-Inflammatory Drugs on Renal Prostaglandins and Cyclooxygenase-2 , 2002, Hypertension.
[13] R. Bing,et al. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? , 2002, Journal of the American College of Cardiology.
[14] Paul Wallace,et al. Design and performance of a multi-centre randomised controlled trial and economic evaluation of joint tele-consultations [ISRCTN54264250] , 2002, BMC family practice.
[15] T. Schnitzer,et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. , 2002, JAMA.
[16] J. Bolognese,et al. A Comparison of Adverse Renovascular Experiences Among Osteoarthritis Patients Treated with Rofecoxib and Comparator Non-selective Non-steroidal Anti-inflammatory Agents , 2002, Current medical research and opinion.
[17] C. Clish,et al. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. , 2001, Biochemical and biophysical research communications.
[18] B. Krämer,et al. Inhibition of COX-2 counteracts the effects of diuretics in rats. , 2001, Kidney international.
[19] T. Hishinuma,et al. Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.
[20] F. Rodríguez,et al. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. , 2001, American journal of physiology. Renal physiology.
[21] M. Perazella,et al. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. , 2001, The American journal of medicine.
[22] R. Poduri,et al. Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR. , 2001, American journal of physiology. Heart and circulatory physiology.
[23] J. L. Rocha,et al. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib , 2001, The Lancet.
[24] S. Laufer,et al. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. , 2001, Pharmacological research.
[25] P. Ambühl,et al. Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. , 2001, Swiss medical weekly.
[26] A. Whelton,et al. Cyclooxygenase-2–Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients , 2001, American journal of therapeutics.
[27] M. Breyer,et al. Cyclooxygenase 2 and the kidney , 2001, Current opinion in nephrology and hypertension.
[28] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[29] S. Swan,et al. Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet , 2000, Annals of Internal Medicine.
[30] P. Isakson,et al. Effects of celecoxib and naproxen on renal function in the elderly. , 2000, Archives of internal medicine.
[31] Barry R. Davis,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.
[32] J. Wallace,et al. Selective cyclo‐oxygenase‐2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence , 2000, British journal of pharmacology.
[33] J. Kaye,et al. Apolipoprotein E ε4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.
[34] J. Schnermann,et al. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. , 1999, The American journal of physiology.
[35] O. Laneuville,et al. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. , 1999, Journal of the American Society of Nephrology : JASN.
[36] B. Connolly,et al. Immunolocalization of cyclooxygenase‐2 in the macula densa of human elderly , 1999, FEBS letters.
[37] J. Mcgiff,et al. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. , 1999, American journal of physiology. Renal physiology.
[38] M. Burnier,et al. Renal effects of selective cyclooxygenase‐2 inhibition in normotensive salt‐depleted subjects , 1999, Clinical pharmacology and therapeutics.
[39] A. Whelton. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. , 1999, The American journal of medicine.
[40] J. Masferrer,et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. , 1999, Gastroenterology.
[41] G. FitzGerald,et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.
[42] J. Wallace,et al. Limited anti‐inflammatory efficacy of cyclo‐oxygenase‐2 inhibition in carrageenan‐airpouch inflammation , 1999, British journal of pharmacology.
[43] Tianxin Yang,et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. , 1998, American journal of physiology. Renal physiology.
[44] M. Vasseur,et al. Direct inhibitory effect of CCCP on the Cl--H+ symporter of the guinea pig ileal brush-border membrane. , 1998, American journal of physiology. Cell physiology.
[45] J. Masferrer,et al. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. , 1997, Hypertension.
[46] H. Seyberth,et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. , 1997, The American journal of physiology.
[47] R. O. Day,et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. , 1996, Journal of human hypertension.
[48] C. Nickerson-Nutter,et al. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. , 1996, Arthritis and rheumatism.
[49] T. Lee,et al. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. , 1995, American journal of respiratory and critical care medicine.
[50] C. F. Richards. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta analysis , 1995 .
[51] S. Laufer,et al. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. , 1995, Arzneimittel-Forschung.
[52] H. Jacobson,et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. , 1994, The Journal of clinical investigation.
[53] R. Day,et al. Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis , 1994, Annals of Internal Medicine.
[54] T. Kita,et al. The role of peptide leukotrienes in renal failure induced by a tourniquet. , 1994, Forensic science international.
[55] D. Felson,et al. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. , 1993, Archives of internal medicine.
[56] E. Gulbins,et al. Cysteinyl leukotriene actions on the microcirculation of the normal and split hydronephrotic rat kidney , 1991, European journal of clinical investigation.
[57] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[58] M. Yaron,et al. Nonsteroidal anti-inflammatory drugs, and hypertension. , 1988, Annals of internal medicine.
[59] L. Wilkins. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-Year findings of the hypertension detection and follow-up program. , 1984, Hypertension.
[60] S. Brodsky,et al. Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. , 2001, American journal of physiology. Renal physiology.
[61] A. Hartner,et al. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. , 1998, Hypertension.
[62] P. D. de Leeuw. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. , 1996, Drugs.